The next generation biopharmaceuticals
David Bejker, M.Sc. Chief Executive Officer
Mr. Bejker has experience from the biotech industry both as an investor and as a business developer. Most recently he worked at HealthCap, a family of multi stage venture capital funds. Bejker has previously worked with business development at Affibody. Mr. Bejker holds a M.Sc. in Business and Economics from the Stockholm School of Economics, where he was awarded the Karl-Adam Bonnier Scholarship to Darden Graduate Business School, Charlotteville, Virginia.
Johan Stuart, M.Sc. Chief Financial Officer
Mr. Stuart has a M.Sc. in Finance and Business Administration from the Stockholm School of Economics. He has more than 15 years’ experience as CFO of listed and unlisted companies, and has been involved in three Initial Public Offerings. Most recently he was CFO of the Swedish life science company XCounter AB, which he helped list on the AIM market of the London Stock Exchange in 2006.
Karin Nord, Ph.D. SVP Research Operations
Dr. Nord is one of the co-founders of Affibody and was one of the first employees; she had an important role in the establishment of the company in 1998. Dr. Nord received her Ph.D., which included pioneering work on Affibody® molecules, from the Royal Institute of Technology in Stockholm in 1999. Dr. Nord was the lead author of the first report on Affibody® molecules, published in Nature Biotechnology in 1997.
Fredrik Frejd, Ph.D., Prof. CSO
Prof. Frejd has over fifteen years of experience in life science research with particular expertise in tumor biology, phage display and therapeutic protein engineering of antibody fragments and alternative scaffolds. He joined Affibody AB in 2002. Dr. Frejd is an adjunct professor at the unit for Biomedical radiation sciences, Uppsala University.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q3 (Nov. 15, 2019)